J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
More News related to SNY
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
- Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Q3 '09 Earning and Outlook
J.P. Morgan downgrades Sanofi-Aventis (NYSE: SNY) from Overweight to Neutral.
To see more analyst ratings on SNY Click Here.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Related Categories
DowngradesStocks Mentioned
-0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
